A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease
Sponsor: Agios Pharmaceuticals, Inc.
Principal Investigator: Bogdan Dumitriu, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
Sponsor: Rebiotix
Principal Investigator: David Yoho, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain
Sponsor: Janssen Scientific Affairs, LLC
Principal Investigator: Michael Horberg, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults with Essential Tremor
Sponsor: Praxis Precision Medicines
Principal Investigator: Ejaz Shamim, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A221805 – Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Sponsor: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) S-0820
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
ALCHEMIST- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors
Sponsor: Arcus Biosciences, Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Sponsor: National Cancer Institute (NCI), Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Breast Cancer Weight Loss Study (BWEL Study)
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon C Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Sponsor: NRG Oncology
Principal Investigator: Leon C Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Sponsor: Alliance for Clinical Trials in Oncology, American College of Radiology Imaging Network, National Cancer Institute (NCI)
Principal Investigator: Amadea Tette, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Sponsor: Curium US LLC
Principal Investigator: Philipose Mulugeta, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Sponsor: National Cancer Institute
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Sponsor: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Sponsor: ECOG-ACRIN Cancer Research Group
Principal Investigator: Ainsley Maclean, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A221805 – Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Sponsor: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) S-0820
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
ALCHEMIST- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors
Sponsor: Arcus Biosciences, Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Sponsor: National Cancer Institute (NCI), Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Breast Cancer Weight Loss Study (BWEL Study)
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon C Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Sponsor: NRG Oncology
Principal Investigator: Leon C Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Sponsor: Alliance for Clinical Trials in Oncology, American College of Radiology Imaging Network, National Cancer Institute (NCI)
Principal Investigator: Amadea Tette, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Sponsor: Curium US LLC
Principal Investigator: Philipose Mulugeta, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Sponsor: National Cancer Institute
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Sponsor: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Sponsor: ECOG-ACRIN Cancer Research Group
Principal Investigator: Ainsley Maclean, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
An Open-label, Non-randomized, Prospective Observational Cohort Study to Assess Post Procedural Outcomes in Two Cohorts of Women Who Chose to Undergo Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
Sponsor: Bayer
Principal Investigator: Jill Finkelstein, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
Phase II/III Study of Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Sponsor: National Cancer Institute (NCI), NRG / NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969